标题
Emerging Roles of ALK in Immunity and Insights for Immunotherapy
作者
关键词
-
出版物
Cancers
Volume 12, Issue 2, Pages 426
出版商
MDPI AG
发表日期
2020-02-24
DOI
10.3390/cancers12020426
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Targeting ALK in Cancer: Therapeutic Potential of Proapoptotic Peptides
- (2019) Arthur Aubry et al. Cancers
- LDK378 improves micro- and macro-circulation via alleviating STING-mediated inflammatory injury in a Sepsis rat model induced by Cecal ligation and puncture
- (2019) Weiwei Ge et al. Journal of Inflammation-London
- NPM-ALK-reactive T-cell responses in children and adolescents with NPM-ALK positive anaplastic large cell lymphoma
- (2019) Vijay Kumar Singh et al. OncoImmunology
- A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion
- (2019) Kazem Nouri et al. FASEB JOURNAL
- PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma
- (2019) Jing Shen et al. MODERN PATHOLOGY
- ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome
- (2019) Claire Y Oh et al. Cancer Immunology Research
- ALK is required for NLRP3 inflammasome activation in macrophages
- (2018) Bibo Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation — Positive Advanced Non–Small Cell Lung Cancer (CheckMate 370)
- (2018) David R. Spigel et al. Journal of Thoracic Oncology
- A Recurrent Mutation in Anaplastic Lymphoma Kinase with Distinct Neoepitope Conformations
- (2018) Jugmohit S. Toor et al. Frontiers in Immunology
- Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).
- (2018) Dong-Wan Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.
- (2018) Alice Tsang Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer
- (2018) Su-Jung Kim et al. Cancer Research and Treatment
- Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
- (2017) Fabian Knörr et al. HAEMATOLOGICA
- Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase
- (2017) Alec J. Walker et al. MOLECULAR THERAPY
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- ALKFusions in a Wide Variety of Tumor Types Respond to Anti‐ALK Targeted Therapy
- (2017) Jeffrey S. Ross et al. ONCOLOGIST
- Efficacy of nivolumab in a patient with systemic refractory ALK+ anaplastic large cell lymphoma
- (2017) Charlotte Rigaud et al. PEDIATRIC BLOOD & CANCER
- ALK is a therapeutic target for lethal sepsis
- (2017) Ling Zeng et al. Science Translational Medicine
- Epitope mapping of spontaneous autoantibodies to anaplastic lymphoma kinase (ALK) in non-small cell lung cancer
- (2017) Mark M. Awad et al. Oncotarget
- Blood cytokine concentrations in pediatric patients with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma
- (2017) Fabian Knörr et al. HAEMATOLOGICA
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK
- (2016) Christine Damm-Welk et al. Journal of Cancer
- Abstract A021: Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers
- (2016) Rafael B. Blasco Cancer Immunology Research
- 351OInduction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non–small cell lung cancer
- (2015) K. Ota et al. ANNALS OF ONCOLOGY
- Targeted Disruption of ALK Reveals a Potential Role in Hypogonadotropic Hypogonadism
- (2015) Barbara Witek et al. PLoS One
- Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions
- (2015) Andrey V. Reshetnyak et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase
- (2015) Jikui Guan et al. eLife
- Efficacy of a Cancer Vaccine against ALK-Rearranged Lung Tumors
- (2015) C. Voena et al. Cancer Immunology Research
- Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients
- (2015) Shaodong Hong et al. OncoImmunology
- PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
- (2014) A D'Incecco et al. BRITISH JOURNAL OF CANCER
- ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma
- (2014) Scott C. Bresler et al. CANCER CELL
- ALKin Lung Cancer: Past, Present, and Future
- (2013) Alice T. Shaw et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of Anaplastic Lymphoma Kinase as a Potential Therapeutic Target in Ovarian Cancer
- (2012) H. Ren et al. CANCER RESEARCH
- Use of minimal disseminated disease and immunity to NPM-ALK antigen to stratify ALK-positive ALCL patients with different prognosis
- (2012) L Mussolin et al. LEUKEMIA
- Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
- (2012) E L Carpenter et al. ONCOGENE
- ALK-Activating Homologous Mutations in LTK Induce Cellular Transformation
- (2012) J. Devon Roll et al. PLoS One
- Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk
- (2010) K. Ait-Tahar et al. BLOOD
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Renal cell carcinoma with novel VCL–ALK fusion: new representative of ALK-associated tumor spectrum
- (2010) Larisa V Debelenko et al. MODERN PATHOLOGY
- Studies of Phosphoproteomic Changes Induced by Nucleophosmin-Anaplastic Lymphoma Kinase (ALK) Highlight Deregulation of Tumor Necrosis Factor (TNF)/Fas/TNF-related Apoptosis-induced Ligand Signaling Pathway in ALK-positive Anaplastic Large Cell Lymphoma
- (2010) Fang Wu et al. MOLECULAR & CELLULAR PROTEOMICS
- Exon Array Profiling Detects EML4-ALK Fusion in Breast, Colorectal, and Non-Small Cell Lung Cancers
- (2009) E. Lin et al. MOLECULAR CANCER RESEARCH
- Effect of single-chain antibody targeting of the ligand-binding domain in the anaplastic lymphoma kinase receptor
- (2009) D C Stylianou et al. ONCOGENE
- Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK+ anaplastic large cell lymphoma
- (2008) J Dien Bard et al. LEUKEMIA
- Kinetics of humoral response to ALK and its relationship with minimal residual disease in pediatric ALCL
- (2008) L Mussolin et al. LEUKEMIA
- Immune privilege or privileged immunity?
- (2008) J V Forrester et al. Mucosal Immunology
- The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
- (2008) Roberto Chiarle et al. NATURE MEDICINE
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
- (2008) M. Marzec et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation